Breaks Categories: News

TuesdayOct 31, 2023 2:01 pm

BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) to Host Third Quarter 2023 Results Conference Call

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only credit card-size 3D-vector electrocardiogram (“VECG”) platform for patient use at home, announced that it will hold a conference call on Tuesday, Nov. 14, 2023, at 4:30 p.m. Eastern Time to discuss its results for the third quarter ended Sept. 30, 2023. The company will also review recent announcements, ongoing initiatives and anticipated 2024 milestones. HeartBeam CEO and Founder Branislav Vajdic, PhD, President Robert Eno and CFO Richard Brounstein will host the call, followed by a question-and-answer period. Accompanying the conference call will be a presentation, which…

Continue Reading

TuesdayOct 31, 2023 12:06 pm

BioMedNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) Acquires Research Assets to Accelerate PAX-101 NDA Submission

PaxMedica (NASDAQ: PXMD), a pioneering biopharmaceutical company specializing in cutting-edge treatments for neurological disorders, today announced the successful acquisition of certain suramin research assets from Rediscovery Life Sciences (“RLS”). The assets were previously dedicated to the study of suramin’s potential efficacy in treating acute kidney injury resulting from chronic kidney disease. According to the announcement, the newly acquired data from RLS will play a crucial role in bolstering PaxMedica’s ongoing efforts to support the submission for the approval of PAX-101, specifically for the treatment of African sleeping sickness caused by the Trypanosoma brucei rhodesiense parasite. “Acquiring the research assets from…

Continue Reading

MondayOct 30, 2023 12:20 pm

BioMedNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) Reports on 1-for-17 Reverse Stock Split

PaxMedica (NASDAQ: PXMD), a clinical-stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (“APT”) for the treatment of autism spectrum disorder (“ASD”) and other serious conditions with intractable neurologic symptoms, has released information regarding its 1-for-17 reverse stock split. According to the announcement, as a result of the reverse stock split of PaxMedica’s common stock that became effective at 8:03 a.m. ET today, the company’s common stock will begin trading on a split-adjusted basis tomorrow, Oct. 31, 2023, when the market opens. The company noted that its common stock will continue to trade under the existing trading symbol PXMD.…

Continue Reading

MondayOct 30, 2023 11:31 am

BioMedNewsBreaks – Safety Shot Inc. (NASDAQ: SHOT) Announces Planned Launch of Its Highly Anticipated Wellness Beverage

Safety Shot (NASDAQ: SHOT) today announced the upcoming direct-to-consumer launch of Safety Shot, the first patented beverage on Earth that helps people feel better faster by reducing blood alcohol content and boosting clarity. Beginning the first week of December 2023, the beverage will be available for retail purchase at www.DrinkSafetyShot.com and www.Amazon.com. In addition, the company plans to launch business-to-business sales of Safety Shot to distributors, retailers, restaurants and bars in the first quarter of 2024. “We’re very excited to launch Safety Shot through our multichannel strategy designed to dominate e-commerce, quickly win retail shelf space, and establish longstanding ties…

Continue Reading

MondayOct 30, 2023 10:41 am

BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Announces Participation at BIO-Europe Munich 2023

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative inflammation and immunology (“I&I”) biological products primarily for the treatment of autoimmune and infectious diseases, will be attending and participating in BIO-Europe, one of Europe’s premier pharmaceutical industry partnering events. The event is slated for Nov. 6­–8, 2023, in Munich, Germany. According to the announcement, Scinai will showcase both its CDMO services, marketed under the brand Scinai Bioservices, and its in-house nanosized VHH antibody-based therapeutics pipeline. In addition, management will be available to meet with potential partners and clients. Scinai offers a state-of-the-art manufacturing facility for biopharmaceutical…

Continue Reading

FridayOct 27, 2023 11:43 am

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Secures $5.2M in Private Placement and Preferred Investment Option Offerings

InMed Pharmaceuticals (NASDAQ: INM) is a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs. The company today announced that it has closed its offering for the issuance and sale of 3,012,049 pre-funded warrants and preferred investment options to purchase up to an aggregate of 3,012,049 common shares, at a purchase price of $0.83 per pre-funded and associated preferred investment option, in a private placement priced at-the-market under Nasdaq rules. Per a previously announced definitive agreement with respect to certain of its outstanding preferred investment options issued in November 2022 and exercisable for 3,272,733…

Continue Reading

FridayOct 27, 2023 10:43 am

BioMedNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) Reports on Publication of Low-Dose Suramin for ASD Research

PaxMedica (NASDAQ: PXMD), a clinical-stage biopharmaceutical company, announced that its groundbreaking research will be published in the “Annals of General Psychiatry,” an internationally recognized scientific psychiatry publication. The research was reported in a manuscript titled “Randomized clinical trial of low-dose suramin intravenous infusions for treatment of autism spectrum disorder,” which will be published by the psychiatry publication. Written by PaxMedica chief medical officer Dr. David Hough, MD, along with nine coauthors, the article reports on the potential of monthly suramin intravenous infusions as a safe and potentially efficacious treatment for the core symptoms of autism spectrum disorder (“ASD”). Coauthors of…

Continue Reading

ThursdayOct 26, 2023 2:30 pm

BioMedNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) Clearing Path to Submit NDA for PAX-101

PaxMedica (NASDAQ: PXMD), a clinical-stage biopharmaceutical company, today announced the completion of a type-B meeting with the FDA. During the live meeting, the company discussed positive results of the recent data from its PAX-HAT-301 study of suramin in stage one human African sleeping sickness caused by trypanosoma brucei rhodesiense, a rare and fatal parasitic disease if left untreated. According to the announcement, PaxMedica received constructive feedback that will aid in the completion of the remaining work necessary to file a New Drug Application (“NDA”) expected in the second half of 2024. “This is an important turning point for our young…

Continue Reading

WednesdayOct 25, 2023 12:06 pm

BioMedNewsBreaks – Safety Shot (NASDAQ: SHOT) Granted Second U.S. Patent for JW-700 Treatment Designed for $1.5B Hair-Growth Market

Safety Shot (NASDAQ: SHOT), a wellness and functional beverage company, announced a “significant milestone” in its development of treatments for androgenetic alopecia, or hair loss: the granting of a second U.S. patent issued for JW-700, a topical treatment designed to improve minoxidil’s efficacy. The patent was issued by the U.S. Patent and Trademark Office. The patent adds to the growing global intellectual property (“IP”) estate for Safety Shots Legacy products. According to the announcement, minoxidil is a common treatment of hair loss sold under brand names including Rogaine(R) and Hair Regrowth for Men(R), and Safety Shot’s JW-700 has been shown to…

Continue Reading

WednesdayOct 25, 2023 10:46 am

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Enters Agreements for Private Placement, Preferred Investment Options

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, has entered into a definitive agreement for the issue and sale of more than 3 million common shares, or prefunded warrants in lieu thereof. Specifically, the company agreed to a private placement of 3,012,049 common shares priced at $0.83 per share. In addition, the company entered an agreement for an associated preferred investment option as well as a definitive agreement regarding specific outstanding preferred investment options issued in November 2022. The announcement outlines specifics of the agreement. The company also…

Continue Reading